Clinical Research Trials

Our extensive experience in clinical research trials, combined with our relationships with leading universities and pharmaceutical companies, supports the advancement of early detection, the slowing of disease progress and our quest to end Alzheimer’s disease.

Research partners include Harvard University, Johns Hopkins University, University of Southern California, Eli Lilly, Eisai, Biogen and many others.

The clinical research trials we use employ the latest methodologies and are based on the most encouraging theories. By joining other participants, you are helping develop medical treatments as well as breakthrough technologies.

We cover participants’ clinical trial costs, offer access to our other memory programs and, in some cases, compensation may be available for time and travel.

If you are interested in participating or learning more about our clinical research trials, please call 305.514.8710 or email EDiaz1@miamijewishhealth.org.

 


 

CURRENT CLINICAL TRIALS

Pharmaceutical study for people with Lewey Body Dementia

  • Name of Study: EISAI Delphia 201
  • Description of Study: This is a Phase II study evaluating the safety, tolerability and efficacy of E2027 in subjects with Dementia with Lewy Bodies.
  • Indication: Meets criteria for probable Dementia with Lewy Bodies Alzheimer’s Disease.
  • Recruiting Participant Age: 50 – 85
  • Duration of Study: 22 weeks

Pharmaceutical study for people with probable MCI – Mild Alzheimer’s Disease

  • Name of Study: EISAI BAN 2401- G000-301
  • Description of Study: This is a Phase III placebo-controlled, double-blind study evaluating the safety, tolerability and efficacy of BAN2401 in subjects with Early Alzheimer’s Disease.
  • Indication: Meets criteria for probable Mild Cognitive Impairment (MCI) – Mild Alzheimer’s Disease
  • Recruiting Participant Age: 50 – 90
  • Duration of Study: 18 months (optional open label extension)

Pharmaceutical study of the efficacy of nicotine in the treatment of MCI

  • Name of Study: MIND Study — Long-Term Nicotine Treatment of Mild Cognitive Impairment. Academia Study, Funded by the National Institute on Aging (NIA) and conducted by Vanderbilt University and University of Southern California
  • Description of Study: The purpose of the Memory Improvement through Nicotine Dosing (MIND) phase II study is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with MCI.
  • Indication: Mild Cognitive Impairment or Memory Loss
  • Recruiting Participant Age: 55 years+
  • Duration of Study: 2 years 

Pharmaceutical study for people with Alzheimer’s and agitation

  • Name of Study: Dronabinol – Johns Hopkins
  • Description of Study: This is a Phase II placebo-controlled, double-blind randomized clinical trial of Dronabinol in Nursing Home patients with severe Agitation – AD.
  • Indication: Alzheimer’s Disease with Agitation
  • Recruiting Participant Age: 60 – 90
  • Duration of Study: 3 weeks

Pharmaceutical study for people with moderate Alzheimer’s Disease

  • Name of Study: Genentech – Lauriet GN40040
  • Description of Study: This is a Phase II placebo-controlled, double-blind randomized study assessing the safety and efficacy of MTAU9937A in subjects with Moderate Alzheimer’s Disease.
  • Indication: Moderate Alzheimer’s Disease
  • Recruiting Participant Age: 50 – 85
  • Duration of Study: Approximately 48 weeks (optional open label extension)

Pharmaceutical study for people with Alzheimer’s and agitation

  • Name of Study: S-CitAD – Johns Hopkins
  • Description of Study: This is a Phase II placebo-controlled, masked study assessing the safety, tolerability and efficacy of Escitalopram for Agitation in Alzheimer’s Disease.
  • Indication: Alzheimer’s Disease with Agitation
  • Recruiting Participant Age: 18+
  • Duration of Study: Approximately 24 weeks (12-week treatment period)

Pharmaceutical study for people with MCI – Mild Alzheimer’s Disease

  • Name of Study: Agene Bio – AGB101 MCD
  • Description of Study: This is a Phase III placebo-controlled, double-blind study evaluating the efficacy and safety of AGB101 (low-dose levetiracetam) in subjects with Early Alzheimer’s Disease.
  • Indication: Meets criteria for Mild Cognitive Impairment (MCI) – Mild Alzheimer’s Disease
  • Recruiting Participant Age: 55 – 85
  • Duration of Study: 18 months

 

UPCOMING CLINICAL TRIALS

Pharmaceutical study for people with Alzheimer’s and agitation

  • Name of Study: Avanir – 17 AVP-786-305
  • Description of Study: This is a phase III placebo-controlled, double-blind clinical trial testing the efficacy, safety and tolerability of AVP-786 for treating symptoms of agitation associated with dementia in patients with Dementia of Alzheimer’s type.
  • Indication: Probable Alzheimer’s disease with Moderate-Severe Agitation
  • Recruiting Participant Age: 50 – 90
  • Duration of Study: Approximately 4 months (optional open label extension)

Live Life Better

Contact Us Today